Quantifying assays: A Modeling tale of variability in cancer therapeutics assessed on cancer cells
Roumen Anguelov, G Manjunath, Avulundiah E Phiri, Trevor T Nyakudya,, Priyesh Bipath, June C Serem, Yvette N Hlophe

TL;DR
This paper introduces a mathematical modeling approach to quantify and reduce variability in cancer cell assay data, specifically analyzing inhibition mechanisms in melanoma cells to improve the reliability of experimental inferences.
Contribution
It proposes a theoretical model of cell viability as a function of time and parameters, enhancing data interpretation and reducing variability effects in cancer therapeutics assays.
Findings
Model reduces sensitivity to data variability
Parameters directly interpret biological processes
Improves understanding of inhibition dynamics
Abstract
Inhibiting a signalling pathway concerns controlling the cellular processes of a cancer cell's viability, cell division, and death. Assay protocols created to see if the molecular structures of the drugs being tested have the desired inhibition qualities often show great variability across experiments, and it is imperative to diminish the effects of such variability while inferences are drawn. In this paper we propose the study of experimental data through the lenses of a mathematical model depicting the inhibition mechanism and the activation-inhibition dynamics. The method is exemplified through assay data obtained from the study of inhibition of the CXCL12/CXCR4 activation axis for the melanoma cells. To mitigate the effects of the variability of the data on the cell viability measurement, the cell viability is theoretically constructed as a function of time depending on several…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMonoclonal and Polyclonal Antibodies Research · Computational Drug Discovery Methods · Melanoma and MAPK Pathways
